

We have the size, scale, skills and reach no one else does

83

10

7

Hospitals

Countries

Trusted brands



We have the size, scale, skills and reach no one else does

RM50b

RM18b

RM1.5b


Market Capitalisation

FY2022 Revenue FY2022 Net Income



Declared Dividend

5-Year Dividend Trend



Dividend for FY2022

Dividend 7 sen (MYR) per share: 2.11 cents (SGD)

Ex-Dividend Date 30 March 2023

Record Date 31 March 2023

Payment Date 28 April 2023

IHH Healthcare dividend policy: Not less than 20% of the Group's profit after tax and minority interests, excluding exceptional items, in respect of any financial year shall be distributed to its shareholders

Performance, Best Practices & Good Governance Recognised

AsiaMoney

Most Outstanding Company in Malaysia – Healthcare Sector

The Edge Billion Ringgit Awards

Highest Growth in PAT over 3 years (companies with >RM40bn mkt cap)

Forbes 2022 World's Best Employers

No. 2 Globally in Healthcare & Social Industry











Strong Financial Performance in FY2022






Financial Performance from Q1'20 to Q4'22





IHH Strategy Framework



Organic and Inorganic Growth

Organic


- 1. Improve bed occupancy
- 2. Expand capacity
 - a) Malaysia
 - Pantai Hospital Penang (7-storey medical block)
 - b) Türkiye
 - Acibadem Ataşehir Hospital (300-bed)
 - c) India
 - Fortis Hospital, Greater Noida (200-bed)

Inorganic

Acquisitions:

- a) Türkiye
- Ortopedia Hospital in Adana (50-bed)
- Kent Hospital in Izmir (340-bed)
- b) India
 - Fortis: Medeor hospital in Gurugram (350-bed)







Synergies: Leverage International Scale



- Develop proprietary hospital information system, Cerebral Plus
- Centralised global IT services



Procurement

- Purchasing advantages of global scale
- Drive best practices in inventory management and utilisation



Operations

- Share best practices internationally
- Redefine business and operating models locally




IHH Laboratories Segment:

Already industry leaders, we will develop this new growth peak








Indirectly owned through Fortis, India



Innovation and Digital Transformation



BUILD

MyHealth360

One-stop mobile app developed in-house to provide seamless and holistic suite of services for IHH patients

Al billing

One of the first healthcare groups to use AI to estimate hospital bills; award-winning system developed in-house has ~80% estimate accuracy for inpatient bills

Telemedicine

Rolled out virtual consultation in the heart of the pandemic across all key markets globally



Innovation and Digital Transformation



INVEST & PARTNER

Strategic Investments

Invested in Series B and C funding for Asian Digi health platform Doctor Anywhere


Co-led Series A investment into MedTech developer Us2.ai behind Al echocardiography software

Invested in Series A funding for genomic medicine company Lucence Diagnostics





ROE Enhancement Strategy





Driving the "S" in ESG + leading our sector to net zero



Patients

Earning the trust of our patients

People

Shaping the best place to work for

Public

Nurturing a healthier society

Planet

Protecting our planet

Goal: To be the most trusted private healthcare provider in all our markets by 2025

Goal: To be the employer of choice in private healthcare in all our markets by 2025


Goal: To touch 5 million lives for healthier communities by 2025

Goal: To cap carbon growth by 2025 and achieve carbon net zero by 2050



Goal: To be the most trusted private healthcare provider in all our markets by 2025

- Flatten the curve on medical inflation through VDO and price transparency
- 2. Provide 'always-on' healthcare by **driving digitalisation and innovation**
- **3. Al-powered predictive analytics** and early detection through technology
- 4. Deliver best-in-class patient and staff experiences







Tackling medical inflation and earning trust:

Costs

Value-Driven Outcomes (VDO)













Goal: To touch 5 million lives for healthier communities by 2025

- Implement antimicrobial resistance interventions in line with CDC, WHO and national guidelines by 2025
- 2. Reduce disease burden on cancer and cardiovascular diseases through outreach and engagement initiatives
- 3. Establish public corporate responsibility programmes to reach more of the underserved by end-2023







Build | Innovate | Transform

The world needs a new healthcare model;
We aim to transform healthcare from Asia

We will transform to become a healthcare platform;
Have an "always-on" relationship with patients

Make our healthcare platform sustainable and drive strong, sustainable growth



Care. For g∞d.

